Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 23; no. 2; p. 178
• Main Authors: Sackoff, J E, McFarland, J W, Shin, S S
• Format: Journal Article
• Language: English
• Published: United States 01.02.2000
• Subjects: Adult; African Americans - statistics & numerical data; Ambulatory Care Facilities - trends; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - therapeutic use; CD4 Lymphocyte Count; Drug Prescriptions - statistics & numerical data; Drug Therapy, Combination; European Continental Ancestry Group - statistics & numerical data; Female; Hispanic Americans - statistics & numerical data; HIV Infections - drug therapy; HIV Infections - ethnology; HIV Infections - immunology; Humans; Longitudinal Studies; Male; New York City - epidemiology; Risk Factors; New York City
• ISSN: 1525-4135
• DOI: 10.1097/00042560-200002010-00010

To describe trends in prescriptions for antiretroviral therapies and factors associated with prescriptions for highly active antiretroviral therapy (HAART). Medical records of patients at four HIV clinics in New York City were reviewed every 6 months. For the four 6-month periods 1997 to 1998, we identified patients with a CD4+ nadir <500 cells/microl; sample sizes were 434, 432, 503, and 643, respectively. Trends in HAART prescriptions were tested by logistic regression using robust variance estimates because some patients contributed more than one time period. Associations between HAART prescriptions and patient characteristics were tested by chi2 and multiple logistic regression analysis. Patients were predominantly black or Hispanic (89%-90%) and male (66%-68%), and injection drug use was the most prevalent HIV risk (38%-49%). From 1997 to 1998, HAART prescriptions increased from 54% to 89% of antiretroviral prescriptions, and the proportion that included an nonnucleoside reverse transcriptase inhibitors (NNRTI) increased from 3% to 10%. HAART prescriptions were inversely associated with CD4+ nadir group during all time periods, and in the second half of 1998, patients with CD4+ nadir between 50 and 199 cells/microl were as likely to be prescribed HAART as the most immunosuppressed patients (CD4+ nadir <50 cells/microl; 91% versus 92%). HAART prescriptions were associated with clinic, HIV risk, and other patient characteristics in some time periods but not consistently. In these four HIV clinics, prescriptions for HAART increased significantly from 1997 to 1998, leveling off at 89% in the second half of 1998. Increasingly, HAART was prescribed for healthier patients and included an NNRTI.